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ABSTRACT  
Obesity is characterized by uncontrolled expansion of adipose tissue mass, resulting in adipocyte 
hypertrophy (increased adipocyte size) and hyperplasia (increased number of adipocytes). The 
number of adipose cells is directly related to adipocyte differentiation process from stromal 
vascular cells to mature adipocytes. It is known that epigenetic factors influence adipose 
differentiation program. However, how specific epigenome modifiers affect white adipocyte 
differentiation and metabolic phenotype is still matter of research. Here, we provide evidence that 
class I histone deacetylases (HDACs) are involved both in the differentiation of adipocytes and in 
determining the metabolic features of these cells. We demonstrate that inhibition of class I 
HDACs from the very first stage of differentiation amplifies the differentiation process and 
imprints cells toward a highly oxidative phenotype.  These effects are related to the capacity of 
the inhibitor to modulate H3K27 acetylation on enhancer regions regulating Pparg and Ucp1 
genes. These epigenomic modifications result in improved white adipocyte functionality and 
metabolism and induce browning. Collectively, our results show that modulation of class I 
HDAC activity regulates the metabolic phenotype of white adipocytes via epigenetic imprinting 
on a key histone mark. 
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1. INTRODUCTION 
In recent years increasing evidences of a link between epigenetics, metabolism and related 
disorders have been reported [1]. Histone deacetylases (HDACs) are epigenome modifiers that 
compact chromatin and reduce the accessibility for transcription factors to target regions [2]. 
HDACs are divided into four classes: class I HDACs (HDAC1, 2, 3, and 8) [3] are located in the 
nucleus and exert the most relevant deacetylase activity, class II HDACs (HDACs 4, 5, 6, 7, 9, 
and 10) shuttle from cytoplasm to nucleus and feature minimal histone deacetylase activity [4], 
class III (sirtuins) deacetylase activity requires NAD+ hydrolysis as a cofactor [5], therefore 
sirtuins act as metabolic sensors of intracellular NAD+/NADH ratio. HDAC11 is the only 
member of class IV HDACs although its function is still poorly understood [6]. Recent evidences 
demonstrated that HDACs participate in the regulation of energy balance and functionality of 
several metabolic organs, such as skeletal muscle, liver, and adipose tissues [7–10] suggesting 
that it is possible to rewire the metabolic capacity of these tissues through the modulation of 
HDAC activity.  
Obesity is the consequence of an altered energy balance that results in excessive accumulation of 
white adipose tissue (WAT). Upon weight gain, different fat depots expand via hyperplasia 
(increase in the number of adipocytes) and hypertrophy (increase of adipocyte size) [11]. A pool 
of adipocyte precursors is present in adipose tissue even during adulthood and in humans 10% of 
adipocytes are renewed annually [12]. Adipocyte precursors also allow the expansion of adipose 
tissue in response to chronic caloric overload.  
The literature of the last decade demonstrated that “browning´ of WAT, a process whereby WAT 
acquires metabolic features typical of brown adipose tissue (BAT), increases energy expenditure 
and attenuates the metabolic impairment consequent to the excessive accumulation of this depot 
[13]. Our group previously demonstrated that selective inhibition of class I HDACs is a 
successful strategy to counteract genetic and diet-induced obesity [14,15], pinpointing the role of 
these enzymes as key regulators of energy metabolism. We showed that the class I HDAC 
inhibitor MS-275 promotes functionality and oxidative metabolism of white fat in db/db and DIO 
(diet-induced obese) mice, determining a switch toward a brown-like phenotype. Although it has 
been shown that HDACs participate in the regulation of signaling pathways regulating 
adipogenesis [16], their role in adipose differentiation is still unclear, since different investigators 
provided conflicting evidences for both activating and repressing effect [17,18]. In this study, we 
provide new evidences of the role of class I HDACs in adipocyte differentiation and in the 
determination of their metabolic phenotype. We found that the class I selective inhibitor MS-275 
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is able to remodel white adipocyte phenotype, especially when adipose precursors are 
differentiated in the presence of the inhibitor. MS-275 in fact upregulates Pparg and Ucp1 by 
increasing H3K27 acetylation in enhancer regions. This epigenome modification has been shown 
to mark activation of poised enhancers and concomitantly to establish promoter-enhancer loops, 
which favors co-activators recruitment and ultimately activation of target genes [19]. Moreover, 
MS-275 increases the expression of Ppara and its target genes and induces higher oxidative 
capacity. Altogether our results provide evidences of the role of class I HDACs in a crucial phase 
of differentiation that affects the metabolic signature of adipocytes, indicating how epigenome 
modifications impinge on the commitment towards a specific metabolic phenotype of fat cells. 
 
2. MATERIALS AND METHODS 
Cell culture - C3H/10T1/2, Clone 8 (ATCC® CCL-226™) were maintained in Dulbecco¶s 
modified Eagle¶s medium supplemented with 10% Fetal Bovine Serum (FBS, Euroclone), 1% 
glutamine (Life Technologies) and 1% penicillin/streptomycin (Pen/Strep, Life Technologies). 
During differentiation cells were maintained for 3 days in medium supplemented with 5 ȝg/ml 
insulin, 500 PM 3-isobutyl-1-methylxanthine (IBMX, Sigma Aldrich), 2 ȝg/ml dexamethasone 
(Sigma Aldrich), 5ȝM rosiglitazone (Cayman Chemicals), and then switched to medium 
supplemented with 5 ȝg/ml insulin for 6 to 8 days. DMSO, 1ȝM MS-275 or 10 ȝM garcinol 
(Cayman Chemicals) was added during differentiation or in the last 24 hours of differentiation 
(i.e., terminally differentiated adipocytes). For experiments in Figure 4D, MS-275 was purchased 
from Sigma Aldrich. All experiments were repeated at least 3 times, unless otherwise stated. 
Determination of lipid droplet size in C3H/10T1/2 adipocytes - Lipid droplet size was assessed 
by using Photoshop CS6 (Adobe Systems Inc., San Jose, California): images were divided by a 
greed into 9 equal-sized boxes, and all lipid droplets in the three diagonal boxes from left to right 
were counted. For each condition were analyzed at least 4 pictures, from 3 different wells. 
Pictures were taken at 20X magnification using Axiovert Microscope (Zeiss). 
Gene expression - RNA from cell cultures was isolated with TRIzol (Invitrogen) or RA1 lysis 
buffer (Macherey-Nagel) supplemented with C2H6OS, purified using the Nucleospin RNA II kit 
(Macherey-Nagel) and quantitated with Nanodrop (Thermo Scientific, Wilmington, DE). Specific 
mRNA was amplified and quantitated by real time PCR, using iScriptTM One Step RT PCR for 
Probes (Bio-Rad Laboratories), following the manufacturer¶s instructions. Data were normalized 
to 36B4 mRNA and quantitated setting up a standard curve.  
Quantification of lipid content - Quantification of lipid content was performed with Oil Red O 
(ORO) staining: staining was eluted from wells with 1.5ml of 100% isopropanol (10 minutes 
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incubation) and absorbance was measured (500 nm, 0.5 sec reading). ORO staining quantification 
was normalized for total RNA or protein content. 
Glycerol release - At the end of experiment, cell culture medium from C3H/10T1/2 cells grown 
and differentiated in 12-well plates was collected. Glycerol release in cell medium, as an index of 
lipolysis, was measured with Triglyceride Dosage Kit (Sentinel) and normalized for total RNA 
content. 
Protein analysis - C3H/10T1/2 cells cultured in 6-well plate were lysed with SDS sample buffer 
(20% glycerol, 4% SDS, 100 mM Tris-HCl pH 6.8, 100 mM dithiothreitol, 0.002% bromophenol 
blue), 1mM protease inhibitors (Sigma), and homogenized with TissueLyser (Qiagen). Tissue 
lysates were separated by SDS-PAGE and transferred onto nitrocellulose membranes, and sample 
loading and transfer evaluated by Ponceau staining. Membranes were then blocked in 5% non fat 
dry milk in 1X TBS-t or 5% BSA in 1X TBS-t and incubated with PPARJ antibody (sc7273, 
Santa Cruz Biotechnology), ATGL antibody (#2138s, Cell Signaling), HSP90D/E antibody  (sc-
69703, Santa Cruz) and E-actin antibody (A5441, Sigma). HRP-conjugated goat anti-mouse 
(Sigma-Aldrich), HRP-conjugated IgG goat anti-rabbit #7074 (Cell Signaling) and HRP-
conjugated IgG horse anti-mouse #7076 (Cell Signaling) secondary antibodies were used for 
detection with chemiluminescence (ECL, Pierce).  
Chromatin immunoprecipitation -C3H/10T1/2 cells differentiated for 12 hours or for 9 days in 
presence of DMSO or MS-275 were cross-linked for 10 min with 1% formaldehyde. Chromatin 
was immunoprecipitated with H3K27ac antibody (ab4729, Abcam). After reversing the 
crosslinking by incubation overnight at 65°C, the DNA was cleaned on QIAquick gel extraction 
kit columns (QIAGEN).  
Statistical analyses - Statistical analysis was performed using the unpaired two-tailed Student t 
test or One-way ANOVA with Tukey as post hoc test or Two-way ANOVA with Tukey as post 
hoc test with GraphPad PRISM (San Diego, CA). 
 
3. RESULTS 
Class I HDAC inhibition stimulates adipogenic potential - Our previous results demonstrated 
that inhibition of class I HDACs counteracts metabolic impairments in a genetic and in a diet 
induced model of obesity (DIO) [14,15]. In db/db and DIO mice, inhibition of class I HDACs 
enhanced white adipose tissue functionality and promoted browning of this fat depot. These 
results raised new questions about the mechanism underlying the effects of MS-275 in WAT. 
This tissue is indeed a plastic organ [19] that contains both adipose precursors and mature 
adipocytes. To tease out the mechanisms underlying the effects on WAT, we asked whether the 
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class I HDAC inhibitor MS-275 affects the phenotype of WAT by acting on adipocyte precursors 
or on terminally differentiated adipocytes. To address this question, we treated C3H/10T1/2 
mesenchymal stem cells at different stages of differentiation with the class I HDAC inhibitor MS-
275. We chose C3H/10T1/2 cells as they are considered early adipocyte precursors [20], thus they 
represent an ideal model to investigate the effect of the treatment on pre-adipocytes. We treated 
cells with vehicle (DMSO) or with 1PM MS-275 from the beginning of differentiation program 
(i.e., day 0 of the experiment, Figure 1A). Strikingly, when cells were differentiated in the 
presence of MS-275 they showed a clear reduction of lipid droplet size (Figure 1B, 1C). However, 
ORO staining revealed no differences in total lipid content under both tested conditions (Figure 
1B, 1D), suggesting that class I HDAC inhibition did not affect the capacity of adipocytes to store 
total lipids, rather it modified the characteristics of lipid droplets. Notably, when differentiated in 
the presence of MS-275, cells featured high expression of perilipin (Plin) (Figure 1E), a PPARJ 
target gene crucial in the formation of lipid droplets [21]. Treatment of C3H/10T1/2 pre-
adipocytes with the class I HDAC inhibitor during differentiation program, in fact, upregulated 
Pparg by 2-fold and, consequently, the adipose markers fatty acid binding protein 4 (Fabp4), 
adiponectin (Adipoq), the glucose transporter 4 (Glut4) and the transcription factor 
CAAT/enhancer binding protein D (Cebpa) (Figure 1E). Accordingly, PPARJ protein 
accumulation was induced by treatment with MS-275 during differentiation (Figure 1F). 
Intriguingly, when we treated terminally differentiated adipocytes with vehicle (DMSO) or with 
1PM MS-275 (Figure 2A) we found no differences on adipocyte morphology (Figure 2B) and 
lipid accumulation (Figure 2C, 2D). Analysis of expression of markers of adipocyte functionality 
revealed no changes in Pparg and Cebpa, a modest though statistical significant reduction in the 
expression of Plin, Adipoq and Glut4 and an increase of Fabp4 expression (Figure 2E, 2F). This 
different trend in the expression of genes belonging to the same pathway suggests that Pparg 
transcriptional network is not fully activated when cells are treated with MS-275 at the end of 
differentiation. The increased expression of Fabp4 in terminally adipocytes treated with MS-275 
suggests that class I HDAC inhibition may directly target this gene. 
These results reveal that class I HDAC inhibition influences adipose differentiation and 
expression of adipocyte functionality markers only if cells are exposed to the inhibitor from the 
beginning of differentiation program, suggesting that class I HDACs regulate the differentiation 
program of preadipocytes. Kinetic experiments demonstrated that inhibition of class I HDACs 
significantly increased Pparg expression from day 5 of differentiation (Figure 3A), reaching a 
plateau at day 9. Accordingly, MS-275 boosted the expression of other adipogenic genes Plin, 
Fabp4, Adipoq, Glut4 and Cebpa in most of the cases from day 5 of differentiation (Figure 3A). 
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To assess whether the early events of differentiation are crucial to determine the cell fate of 
adipocyte precursors, we exposed C3H10T1/2 cells to MS-275 only during the first 72 hours of 
adipose differentiation. We noticed that the inhibitor was still able to upregulate the expression of 
adipose markers even after removing it (Figure 3B). Collectively, these results suggest that MS-
275 imprinted cells during the initial phase of differentiation and that class I HDACs impact key 
events during the early stage of adipogenesis. 
Inhibition of class I HDACs stimulates oxidative metabolism and browning of differentiating 
adipocytes - The reduced lipid droplets size in cells differentiated in presence of MS-275 
prompted us to ask whether inhibition of class I HDACs affected the expression of metabolic 
genes. Treatment with MS-275 from the beginning of differentiation jncreased expression of lipid 
internalization and lipolysis genes (e. g., Cd36, Lpl, Lipe, Atgl) (Figure 4A). Accordingly, ATGL 
protein levels were increased in MS-275 treated cells (Figure 4B). This was mirrored by 
increased glycerol release in the medium of these cells, a functional read-out of increased 
lipolysis (Fig. 4C). Moreover, MS-275 strongly stimulated pathways of mitochondrial fatty acid 
E-oxidation (e.g., Cpt1b, Acadl, Acadm, Hadh) and of Ppara, an important regulator of fatty acid 
oxidative metabolic pathways (Figure 4D). In cells differentiated in presence of MS-275 we 
detected higher expression of genes belonging to the TCA cycle (Idh3a, Suclg1) and branched-
chain amino acid catabolism (Bckdhb), electron transport chain (ETC) (Cox6a1, Cox7a1, Etfdh, 
CytC) and mitochondrial biogenesis (Ppargc1a) (Figure 4E), suggesting increased mitochondrial 
activity. Indeed, these data were corroborated by increased signal of MitoTracker® Red CM-
H2Xros (Fig. 4F), a fluorescent dye staining mitochondria with high oxidative activity upon MS-
275 treatment. Higher mitochondrial activity and Ppara expression in white adipocytes often 
correlates with a switch toward a “brown-like´ phenotype. Moreover, we already demonstrated 
that MS-275 was able to induce browning of white fat when administered to obese mice. Thus, 
we measured the expression of browning markers in cells treated with the inhibitor during 
differentiation and, consistent with previous results, we detected higher expression of Ucp1, 
Adrb3, Ppara, Cidea and Elovl3 in response to treatment with MS-275 during differentiation 
(Figure 4G).   
On the contrary, administration of MS-275 in terminally differentiated adipocytes yielded only 
mild effects on fatty acid E-oxidation genes (Figure 5A) and on genes involved in oxidative 
metabolism (Figure 5B), which was paralleled by the lack of changes in mitochondrial oxidative 
activity (Figure 5C). Interestingly, also treatment of fully differentiated cells with MS-275 
increased the expression of the BAT markers Ucp1 and of Elovl3 although the other genes were 
not affected (Figure 5D). 
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Altogether, our results indicate that MS-275 enhanced the oxidative capacity of C3H10T1/2 
adipocytes and induced the expression of BAT markers gene. The effects of the class I HDAC 
inhibitor are more pronounced in differentiating cells than in terminally differentiated adipocytes, 
most likely because the inhibitor is able to remodel cell phenotype in the early phase of 
differentiation due to the higher plasticity of precursors cells.  
Class I HDACs controls acetylation status of enhancer elements regulating Pparg and Ucp1 
genes - To gain molecular insights on the transcriptional effects of MS-275 in white adipocytes, 
we performed chromatin immunoprecipitation experiments in C3H/10T1/2 cells focusing on 
acetylation of H3K27, a known histone mark of active enhancers which are crucial during the 
differentiation stages. The analysis of kinetic gene expression showed that Pparg and Ucp1 genes 
were significantly up-regulated after 12 hours of differentiation (Figure 6A, 6C). We found that at 
this time point  class I HDAC selective inhibitor was already able to increase H3K27 acetylation 
on a recently described potent enhancer element of Pparg gene, even though this increase did not 
reach the statistical meaning (Figure 6B) [22]. Moreover, we also found increased H3K27ac at an 
enhancer region located 13 kb upstream of the transcription start site of Ucp1 gene (Figure 6D), 
which is typically hyper-acetylated during brown adipocyte differentiation [23]. The increased 
H3K27 acetylation in these regulator elements was even stronger in cells differentiated for 9 days 
in the presence of MS275 (Figure 6E, 6F), correlating with stronger up-regulation of these genes 
(Figure 1E and 5A). Furthermore, at this time point, the class I HDAC inhibitor was able to 
increase H3K27 acetylation also in another enhancer element located 5 upstream of the 
transcription start site of Ucp1 gene (Figure 6F), potentiating further the transcription of Ucp1. 
Altogether, these results suggest that inhibition of class I HDACs in differentiating adipocytes 
increases the acetylation of H3K27 at Pparg and Ucp1 enhancers, resulting in higher expression 
of genes governing adipocyte functionality and browning. 
Inhibition of HAT activity prevents adipocyte differentiation and reduces the expression of 
genes for lipolysis, fatty acid E-oxidation, mitochondrial function and brown fat - The effects of 
the class I HDAC inhibitor on the phenotypic switch of adipocytes suggested that HATs could 
have a role on the phenotype of adipocytes. To test this hypothesis, we performed experiments to 
verify the effects of garcinol, a chemical inhibitor of HATs. C3H/10T1/2 preadipocytes were 
treated with garcinol at the beginning of differentiation until the end of the experiment at day 9 
(Figure 7A). At the end of the incubation, C3H/10T1/2 cultures treated with garcinol show a 
clearly diminished number of adipocytes while a greater fraction of cells did not differentiate 
(Figure 7B). Quantification of ORO staining indicates strong reduction of lipid accumulation 
(Figure 7C). Expression analysis of genes encoding markers of adipocyte function, lipolysis and 
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fatty acid E-oxidation (FAO), mitochondria and brown fat reveals that the levels of these mRNAs 
were strongly reduced in cell treated with the HAT inhibitor garcinol. Altogether, these results 
highlight the central importance of HDACs and HATs in determining the metabolic phenotype of 
adipocytes. 
 
4. DISCUSSION 
The role of HDACs in adipose tissue metabolism has emerged recently, however the mechanisms 
whereby they regulate adipose differentiation and functionality are not fully understood. The 
results of this study contribute to fill this gap, shedding light on how class I HDACs regulate 
early stages of adipose differentiation and the acquirement of brown-like phenotype. 
The high plasticity [24] of fat depot is related to the presence of adipocyte precursors within 
adipose tissue [12], which determine the metabolic features in response to environmental cues. 
Our results demonstrate that inhibition of class I HDACs during differentiation strongly 
stimulates adipogenesis. An important finding of our study is that inhibition of class I HDACs in 
the early phase of adipose differentiation (72 hours) imprints cell precursors toward a highly 
oxidative metabolic phenotype. These data suggest higher malleability of the epigenome in the 
first stage of adipose differentiation, allowing the HDAC inhibitor to deeply influence the 
metabolic features of the resulting adipocytes. On the contrary, when cells are terminally 
differentiated and epigenetic signature has already established, the impact of HDAC inhibition on 
adipose differentiation is modest. The reduced expression of Plin in fully differentiated 
adipocytes treated with MS-275 was not accompanied by reduction of lipid droplet size. Based on 
the results on gene expression and morphology analysis performed 24 hours post treatment with 
MS-275, we hypothesize that at this time point changes of gene expression may not be sufficient 
to determine a morphological rearrangement of lipid droplets. We cannot exclude that lipid 
droplets may change their shape later. Also, it should be noted that other proteins are associated 
to lipid droplets and they could compensate the reduced expression of Plin. 
The effects of the class I HDAC inhibitor on adipose differentiation are mostly due to the earlier 
induction of the master regulator of adipogenesis PPARJ. Our results suggest that H3K27 
hyperacetylation of Pparg enhancer, a histone modification that selectively marks active 
enhancers [25], is the “imprinting´ event that primes and leads to the observed phenotype. These 
results are in line with recent evidences showing that during the first hours of differentiation 
H3K27ac is highly dynamic at already poised enhancer regions. Siersbæk and colleagues [26], in 
fact, demonstrated that when differentiation is induced with an adipogenic cocktail these regions 
loop together with promoters and recruit co-regulators. The authors demonstrate that dynamic 
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chromatin looping of promoter-enhancer regions links reprogramming of enhancer activity to 
transcriptional activation of target genes. Histone acetylation levels are determined by the balance 
between the activity of HDACs and histone acetyltransferases (HATs). HATs-mediated 
acetylation plays a relevant role during adipogenesis [27]. As a matter of fact, treatment with 
garcinol, a natural compound which inhibits HATs, induced cell cycle arrest and reduced 
adipocyte differentiation of 3T3-L1 cells [28]. Thus, these evidences clearly demonstrate that the 
dynamic of chromatin rearrangement are crucial to modulate adipose cell fate. 
Another main finding is that inhibition of class I HDACs induce Ppara expression and, 
consequently, potentiates oxidative metabolism by acting mostly in differentiating cells and, to a 
lesser extent, in fully differentiated adipocytes. The strong induction of lipolytic and fatty acid E-
oxidation pathways, along with the induction of other genes like Plin, explains the reduction of 
lipid droplet size upon treatment with MS-275. PPARJ and PPARD induction emerged, in fact, as 
one of the key elements for the acquirement of the MS-275-mediated phenotype, as proved by the 
loss of effects in presence of PPARD/J antagonists. Interestingly, Montgomery et al. [29] showed 
that pre-natal Hdac3 cardiac-specific ablation over-activated PPARD and, consequently, 
increased the expression of genes important for fatty acid uptake and oxidation, electron transport 
chain and oxidative phosphorylation causing myocardial fatty acid accumulation, severe 
hypertrophy and lethality. Although higher PPARD activation is showed to be detrimental in this 
context, this work demonstrated a link between HDACs and PPARD activation. In parallel, post-
natal Hdac3 cardiac and skeletal muscle ablation was shown to be lethal only upon challenge 
with high fat diet [30]. This highlights how inactivation of HDACs in different stages during cell 
differentiation could result in different effects.  
Moreover, in this study inhibition of class I HDACs caused hyperacetylation of H3K27 in two 
different enhancers regulating Ucp1 expression, which is consequently increased. 
Hyperacetylation of these enhancers has been described in differentiated brown adipocytes [23]. 
Consequently, our results highlight an important browning effect. Furthermore, the higher 
expression of Ucp1 could be in part mediated also by increased Pparg expression, whose role in 
the induction of browning in white adipocytes has been described [31]. Recently, it has been 
reported that the browning effect of rosiglitazone in human multipotent adipose-derived stem 
cells (hMADS) occurs only in mature white adipocytes, suggesting that PPARJ-mediated 
browning requires factors that are expressed late in the differentiation of white adipocytes [32]. 
Thus, our results highlight novel factors that promote browning in the early stages of adipocyte 
differentiation via inhibition of class I HDACs. Interestingly, the higher expression of Ucp1 in 
response to MS-275 in both differentiating and terminally differentiated adipocytes suggests that 
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class I HDACs may directly regulate this gene. However, the increased expression of Ucp1 itself 
is not sufficient to establish browning, since in fully differentiated adipocytes treated with MS-
275 we did not observe upregulation of all the other markers except Elovl3 mRNA. In fact, 
release of fatty acids from lipid droplets in response to adrenergic stimulation, is required to 
activate UCP1 in mitochondria [33]. In the resting state, the activity of UCP1 in the 
mitochondrial inner membrane is inhibited by cytosolic purine nucleotides (i.e. ATP). We have 
previously demonstrated that browning of white adipocytes requires metabolic rewiring to 
support the thermogenic program [34]. Therefore, the increased expression of Ucp1 and Elovl3 
genes, observed in differentiated adipocytes treated with MS-275, may not be sufficient for the 
browning phenotype to fully display. Low temperature determines the release of norepinephrine 
(NE) from sympathetic nerves in BAT.  UCP1 operates as a proton carrier activated by long chain 
fatty acids released after adrenergic-stimulated lipolysis [35,36]. The strong induction of lipolytic 
genes (Lipe, Atgl) by MS-275 indicates that inhibition of class I HDACs during the early phase of 
differentiation efficiently activates UCP1, while in terminally differentiated adipocytes, the 
inhibitor increased transcription of Ucp1 but had no effect on lipolysis. It is worth to highlight 
that our investigations aimed to reveal new possible mechanisms that regulates adipogenesis and 
adipocyte metabolism, rather than propose HDAC inhibition as a new pharmacological approach 
to treat obesity. It should be noted that HDAC inhibitors are currently studied as chemotherapy in 
cancer. The main adverse effects associated with the use of HDAC inhibitors in anti-cancer 
therapies during clinical trials were gastrointestinal (nausea, vomiting, anorexia, constipation, 
diarrhea, dehydration and other less common symptoms), fatigue, weight loss, fever, 
hematological changes (thrombocytopenia, anemia and neutropenia), which resolved after the end 
of the treatment, cardiac, metabolic and other neurological, respiratory and infective. Also, deaths 
were reported to occur in clinical trials with HDAC inhibitors, but it is uncertain whether death 
incidence was higher than what usually reported in clinical trials in the field of cancer [37]. With 
respect to possible cardiac toxicity, a systematic review reported that the use of HDAC inhibitors 
frequently caused the appearance of mild cardiac side effects, but it was not possible to state a 
clear incidence of cardiac side effect [38] due to the lack of the complete cardiac parameters and 
the concomitant use of other therapies. Of note, the clinical trial with MS-275 (Entinostat) 
included in this review showed 10.7 % of incidence in heart failure. Altogether, these 
considerations warrant the evaluation of possible side effects of HDAC inhibitors in the field of 
metabolic diseases. At this regard, it is worth mentioning that our previously published data show 
amelioration of the metabolic alterations in pre-clinical models of obesity/insulin resistance (i.e., 
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db/db and DIO mice) treated with MS-275 [14,15]. Furthermore, MS-275 improved hepatic 
functionality in db/db mice, as shown by reduced levels of ALT/AST in the blood. 
In conclusion, our results suggest that the metabolic remodeling mediated by inhibition of class I 
HDACs during the early phase of differentiation stimulates the browning of adipocytes and that 
epigenome alterations can affect the plasticity of precursors towards a different phenotype of 
terminally differentiated fat cells. This study unveils novel aspects of adipocyte differentiation 
and of mechanisms affecting their metabolic phenotype via dynamic epigenome modifications. 
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CAPTIONS 
 
Figure 1. Effect of class I HDAC inhibition in preadipocytes 
A) Experimental paradigm for C3H/10T1/2 cells exposed to vehicle/MS-275 during 
differentiation. B) Cellular morphology and Oil Red O staining of C3H/10T1/2 adipocytes at day 
9 of differentiation in the presence of vehicle/MS-275. C) Quantification of lipid droplet size 
(n=3 biological replicates). D) Oil Red O staining quantification (n=9, from three independent 
experiments) E) Gene expression analysis of C3H/10T1/2 adipocytes at day 9 of differentiation in 
the presence of vehicle/MS-275 (n=12, from four independent experiments). F) Western blot 
analysis of PPARJ in C3H/10T1/2 adipocytes at day 9 of differentiation in the presence of 
vehicle/MS-275. 
Data are presented as mean ± SEM. Statistical analysis: Student¶s t test, *p<0.05, **p<0.01, 
***p<0.001. 
 
Figure 2. Effect of class I HDAC inhibition in differentiated adipocytes 
A) Experimental paradigm for C3H/10T1/2 cells exposed to vehicle/MS-275 during the last 24 
hours of differentiation. B) Cellular morphology and Oil Red O staining of C3H/10T1/2 
adipocytes exposed to vehicle/MS-275 during the last 24 hours of differentiation. C) 
Quantification of lipid droplet size (n=3 biological replicates). D) Oil Red O staining 
quantification (n=9, from three independent experiments) E) Gene expression analysis of 
C3H/10T1/2 adipocytes treated vehicle/MS-275 for 24 hours at the end of differentiation (n=12, 
from four independent experiments). F) Western blot analysis of PPARJ in C3H/10T1/2 
adipocytes treated vehicle/MS-275 for 24 hours at the end of differentiation. 
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Data are presented as mean ± SEM. Statistical analysis: Student¶s t test, *p<0.05, **p<0.01, 
***p<0.001. 
 
Figure 3. Kinetic analysis of class I HDAC inhibition on gene expression 
A) Kinetics of gene expression in C3H/10T1/2 cells exposed to vehicle/MS-275 during all the 
differentiation program (n=3). B) Kinetics of gene expression in C3H/10T1/2 cells exposed to 
vehicle/MS-275 only during the first 3 days of differentiation (n=3).  
Data are presented as mean ± SEM. Statistical analysis: Two-way ANOVA with Tukey¶s as post 
hoc test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 of cells treated with MS-275 vs. cells 
treated with vehicle (DMSO) at the corresponding time point. Although not indicated in the graph, 
statistical analysis indicates that the expression of the analyzed genes increased significantly 
during the differentiation both in the absence and in the presence of MS-275. 
 
Figure 4. Effects of class I HDAC inhibition in preadipocytes on lipolytic, fatty acid E-oxidation, 
mitochondrial, brown fat genes 
A) Expression of genes involved in lipolysis in C3H/10T1/2 adipocytes at day 9 of differentiation 
in the presence of vehicle/MS-275 (n=12, from four independent experiments). B) Western blot 
analysis of ATGL protein levels and related quantification (n=3, data from one single 
experiment). C) Glycerol release in medium from C3H/10T1/2 adipocytes at day 9 of 
differentiation in the presence of vehicle/MS-275 (n=6). D) Expression of genes involved in fatty 
acid E-oxidation in C3H/10T1/2 adipocytes at day 9 of differentiation in the presence of 
vehicle/MS-275 (n=12, from four independent experiments). E) Expression of oxidative 
metabolism genes in C3H/10T1/2 adipocytes at day 9 of differentiation in the presence of 
vehicle/MS-275 (n=12, from four independent experiments). F) Mito Tracker RED in 
C3H/10T1/2 adipocytes at day 9 of differentiation in presence of vehicle/MS-275 (n=24). G) 
Expression of browning genes in C3H/10T1/2 adipocytes at day 9 of differentiation in the 
presence of vehicle/MS-275 (n=12, from four independent experiments).  
Data are presented as mean ± SEM. Statistical analysis: Student¶s t test, *p<0.05, **p<0.01, 
***p<0.001. 
 
Figure 5. Effects of class I HDAC inhibition in differentiated adipocytes on lipolytic, fatty acid 
E-oxidation, mitochondrial, brown fat genes 
A) Expression of genes involved in lipolysis and fatty acid E-oxidation in C3H/10T1/2 adipocytes 
treated vehicle/MS-275 for 24 hours at the end of differentiation (n=12, from four independent 
Journal Pre-proof
Jo
urn
al 
Pre
-pr
oo
f
Class I HDACs in adipose differentiation 
 18 
experiments). B) Expression of oxidative metabolism genes in C3H/10T1/2 adipocytes treated 
vehicle/MS-275 for 24 hours at the end of differentiation (n=12, from four independent 
experiments). C) Mito Tracker RED in C3H/10T1/2 adipocytes treated vehicle/MS-275 for 24 
hours at the end of differentiation (n=24). D) Expression of browning genes in C3H/10T1/2 
adipocytes treated vehicle/MS-275 for 24 hours at the end of differentiation (n=12, from four 
independent experiments). 
Data are presented as mean ± SEM. Statistical analysis: Student¶s t test, *p<0.05, **p<0.01, 
***p<0.001. 
 
Figure 6. ChIP analysis of the epigenetic modifications in the Pparg and Ucp1 enhancers 
induced by the class I HDAC inhibitor MS-275 
A) Pparg expression in C3H/10T1/2 cells exposed to vehicle/MS-275 during the first 12 hours of 
differentiation (n=3). B) H3K27ac ChIP assay on Pparg enhancer region in C3H/10T1/2 cells 
exposed to vehicle/MS-275 during the first 12 hours of differentiation (n=3). C) Ucp1 expression 
in C3H/10T1/2 cells exposed to vehicle/MS-275 during the first 12 hours of differentiation (n=3). 
D) H3K27ac ChIP on Ucp1 enhancer regions in C3H/10T1/2 cells exposed to vehicle/MS-275 
during the first 12 hours of differentiation (n=3). E) H3K27ac ChIP on Pparg enhancer region in 
C3H/10T1/2 adipocytes exposed to vehicle/MS-275 during the differentiation program (9 days) 
(n=3); for the expression level of Pparg refer to figure 1E. F) H3K27ac ChIP on Ucp1 enhancer 
regions in C3H/10T1/2 adipocytes exposed to vehicle/MS-275 during the differentiation program 
(9 days) (n=3); for the expression of Ucp1 refer to figure 4G. 
Data are presented as mean ± SEM. Statistical analysis: Student¶s t test, *p<0.05, **p<0.01, 
***p<0.001. 
 
Figure 7. Effect of the HAT inhibitor garcinol on adipocyte function, lipolysis and fatty acid E-
oxidation, mitochondrial, brown fat genes on differentiating preadipocytes 
A) Experimental paradigm for C3H/10T1/2 cells exposed to vehicle/garcinol during 
differentiation. B) Cell morphology of C3H/10T1/2 adipocytes at day 9 of differentiation in the 
presence of vehicle (0.1% DMSO) or 10 PM garcinol. Top line of images shows unstained 
adipocytes; bottom line of images shows adipocytes stained with Oil Red O. C) 
Spectrophotometric quantification of ORO staining. D) Expression of genes for adipocyte 
function, lipolysis and fatty acid E-oxidation, mitochondrial functions, brown fat at day 9 of 
differentiation in the presence of vehicle (0.1% DMSO) or 10 PM garcinol. 
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Data are presented as mean ± SEM (n=6 from two independent experiments). Statistical analysis: 
Student¶s t test, **p<0.01, ***p<0.001, ****p<0.0001. 
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Highlights 
x Inhibition of class I histone deacetylases promotes adipocyte differentiation 
x Histone deacetylases and histone acetyl transferases regulate adipocyte metabolism 
x Epigenetic imprinting regulates the metabolic phenotype of adipocytes 
x Epigenome modifications in precursor cells affect the metabolic fate of adipocytes 
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